|
Trade Name | LIPOSORBER LA-15 SYSTEM |
Classification Name | apheresis for focal glomerulosclerosis in adult and pediatric patients |
Generic Name | apheresis for focal glomerulosclerosis in adult and pediatric patients |
Applicant |
KANEKA PHARMA AMERICA LLC |
546 fifth ave., 21st floor |
new york, NY 10036 |
|
HDE Number | H120005 |
Date Received | 09/04/2012 |
Decision Date | 10/10/2013 |
Product Code | |
Docket Number | 13M-1322 |
Notice Date | 10/30/2013 |
Advisory Committee |
Gastroenterology |
Supplement Type | hde original |
Expedited Review Granted? | No |
Combination Product | No |
Approval Order Statement Approval for the kaneka liposorber® la-15 system. This device is indicated for use in the treatment of pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when 1) standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments,are unsuccessful or not well tolerated and the patient has a gfr 60 > ml/min/ 1. 73m2; or 2) the patient is post renal transplantation. |
Approval Order | Approval Order |
Summary | Summary of Safety And Probable Benefit |
Labeling | Labeling Labeling Part 2 |
Post-Approval Study | Show Report Schedule and Study Progress |
Supplements: |
S001 S002 S003 S004 S005 S006 S007 S009 S010 S011 S012 S013 S014 S015 S016 S017 S018 S019 S020 S021 S024 S025 |